Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Narlaprevir DDI with Tenofovir and Raltegravir
NCT03537404Phase 1Completed
- Sponsor
- R-Pharm
- Start
- Apr 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of narlaprevir in hepatitis C (HCV) (3 arms), sponsored by R-Pharm. Primary endpoints: Maximum Plasma Concentration at Day 5 and Area Under the Curve over dosing interval at Day 5. Started Apr 2017; status: completed.
02
Drugs
narlaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03537404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03537404.